open access
Primary refractory primary mediastinal lymphoma treated with CAR-T: new possibilities and challenges
Affiliations- Department of Hematology and Bone Marrow Transplantation, University of Medical Sciences, Poznań, Poland
open access
Abstract
Abstract
Keywords
CAR-T; PMBCL; axicabtagene cyloleucel; axi-cel; CRS; ICANS; B-NHL; LBCL; allo-HCT
About this articleTitle
Primary refractory primary mediastinal lymphoma treated with CAR-T: new possibilities and challenges
Journal
Issue
Article type
Clinical vignette
Pages
215-217
Published online
2022-06-10
Page views
2094
Article views/downloads
199
DOI
10.5603/AHP.a2022.0026
Bibliographic record
Acta Haematol Pol 2022;53(3):215-217.
Keywords
CAR-T
PMBCL
axicabtagene cyloleucel
axi-cel
CRS
ICANS
B-NHL
LBCL
allo-HCT
Authors
Krzysztof Żyłka
Dominik Dytfeld
Lidia Gil
References (10)- Lees C, Keane C, Gandhi MK, et al. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019; 185(1): 25–41.
- Crump M, Neelapu S, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16): 1800–1808.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531–2544.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4): 625–638.
- Gil L, Łojko-Dankowska A, Matuszak M, et al. CAR-T cell therapy — toxicity and its management. Acta Haematol Pol. 2020; 51(1): 6–10.
- Jain T, Bar M, Kansagra AJ, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019; 25(12): 2305–2321.
- Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014; 20(6): 872–880.
- Al Zaki A, Feng L, Watson G, et al. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Adv. 2022; 6(9): 2867–2871.
- Figura NB, Robinson TJ, Sim AJ, et al. Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy. Int J Radiat Oncol Biol Phys. 2021; 111(5): 1145–1154.
- Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33(3): 259–275.